| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1038/NRI802 |
| P698 | PubMed publication ID | 12033742 |
| P2093 | author name string | Marc Feldmann | |
| P2860 | cites work | Cloning and expression of cDNA for human lymphotoxin, a lymphokine with tumour necrosis activity | Q24301401 |
| An endotoxin-induced serum factor that causes necrosis of tumors | Q24564406 | ||
| Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis | Q24564656 | ||
| Preliminary results of early clinical trials with the fully human anti-TNFalpha monoclonal antibody D2E7 | Q24675216 | ||
| A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity | Q24675629 | ||
| Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent | Q28191546 | ||
| Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial | Q28202251 | ||
| Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis | Q28239197 | ||
| The nucleotide sequence of human fibroblast interferon cDNA | Q28261941 | ||
| Synthesis in E. coli of a polypeptide with human leukocyte interferon activity | Q28276363 | ||
| Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin | Q28306447 | ||
| Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group | Q29616063 | ||
| Role of cytokines in rheumatoid arthritis | Q29620713 | ||
| Cellular sites of immunologic unresponsiveness | Q33691637 | ||
| PEGylated recombinant human soluble tumour necrosis factor receptor type I (r-Hu-sTNF-RI): novel high affinity TNF receptor designed for chronic inflammatory diseases | Q33782360 | ||
| Infliximab for the treatment of fistulas in patients with Crohn's disease | Q33860666 | ||
| Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group | Q33885648 | ||
| Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? | Q33937489 | ||
| Construction and initial characterization of a mouse-human chimeric anti-TNF antibody | Q34060890 | ||
| Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis | Q34229344 | ||
| Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin | Q34258651 | ||
| Filgrastim (r-metHuG-CSF) in the 21st century: SD/01. | Q34313866 | ||
| Progress in the treatment of rheumatoid arthritis | Q34458770 | ||
| Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis | Q35132863 | ||
| Pig interleukin 1. Purification of two immunologically different leukocyte proteins that cause cartilage resorption, lymphocyte activation, and fever | Q36350997 | ||
| Constitutive activity of the tumor necrosis factor promoter is canceled by the 3' untranslated region in nonmacrophage cell lines; a trans-dominant factor overcomes this suppressive effect | Q36793833 | ||
| Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice | Q37147228 | ||
| Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis | Q37253521 | ||
| Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells | Q37383893 | ||
| Type II collagen autoimmunity in animals and provocations leading to arthritis | Q37783217 | ||
| Rheumatoid arthritis. Pathophysiology and implications for therapy | Q38019708 | ||
| Manipulation of T-cell responses with monoclonal antibodies | Q38201549 | ||
| The mechanism of immunological paralysis. | Q39973375 | ||
| Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab | Q42628068 | ||
| Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis | Q42694138 | ||
| Evidence that rheumatoid arthritis synovial T cells are similar to cytokine-activated T cells: involvement of phosphatidylinositol 3-kinase and nuclear factor kappaB pathways in tumor necrosis factor alpha production in rheumatoid arthritis | Q43873302 | ||
| Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis | Q44064388 | ||
| Designing CD4 immunoadhesins for AIDS therapy | Q46215386 | ||
| Expression of human immune interferon cDNA in E. coli and monkey cells | Q48405865 | ||
| Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. | Q53547618 | ||
| Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). | Q54005785 | ||
| Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α | Q56813295 | ||
| Systemic anti-tumor necrosis factor α therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor α synthesis | Q57350949 | ||
| Adverse reactions to TNF-α inhibitors in rheumatoid arthritis | Q57415315 | ||
| Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. The Cooperative Systematic Studies of Rheumatic Diseases Group | Q67285449 | ||
| Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-alpha | Q68007091 | ||
| Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis | Q68028260 | ||
| Cytokine production in culture by cells isolated from the synovial membrane | Q69229748 | ||
| Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum | Q70399995 | ||
| Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis | Q71160288 | ||
| Interleukin 1 activity in the synovial fluid of patients with rheumatoid arthritis | Q72119458 | ||
| Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75)–Fc Fusion Protein | Q73502940 | ||
| Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group | Q73548256 | ||
| Anaemia of chronic disease in rheumatoid arthritis: in vivo effects of tumour necrosis factor alpha blockade | Q73895634 | ||
| Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial | Q74265787 | ||
| Rheumatoid arthritis | Q74541001 | ||
| Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis | Q74602860 | ||
| Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis | Q77341367 | ||
| P433 | issue | 5 | |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| P304 | page(s) | 364-371 | |
| P577 | publication date | 2002-05-01 | |
| P1433 | published in | Nature Reviews Immunology | Q43355 |
| P1476 | title | Development of anti-TNF therapy for rheumatoid arthritis | |
| P478 | volume | 2 |
| Q39656434 | (Z)-5-(4-methoxybenzylidene) thiazolidine-2, 4-dione ameliorates the adjuvant-induced arthritis via inhibiting the migration of macrophage and down-regulating the cytokine mRNA expression |
| Q35170024 | 17(R)-Resolvin D1 differentially regulates TLR4-mediated responses of primary human macrophages to purified LPS and live E. coli |
| Q89636132 | 4-1BBL Regulates the Polarization of Macrophages, and Inhibition of 4-1BBL Signaling Alleviates Imiquimod-Induced Psoriasis |
| Q95839898 | A 3'UTR modification of the TNF-α mouse gene increases peripheral TNF-α and modulates the Alzheimer-like phenotype in 5XFAD mice |
| Q91944393 | A Comparative Study to Assess the Efficacy, Safety, and Immunogenicity of YLB113 and the Etanercept Reference Product for the Treatment of Patients with Rheumatoid Arthritis |
| Q36099992 | A RANKL mutant used as an inter-species vaccine for efficient immunotherapy of osteoporosis. |
| Q41612628 | A cytokine signal inhibitor for rheumatoid arthritis enhances cancer metastasis via depletion of NK cells in an experimental lung metastasis mouse model of colon cancer |
| Q24796537 | A proinflammatory role for Fas in joints of mice with collagen-induced arthritis |
| Q34363191 | Abrogation of CC chemokine receptor 9 ameliorates collagen-induced arthritis of mice |
| Q35090142 | Active versus passive anti-cytokine antibody therapy against cytokine-associated chronic diseases |
| Q73896817 | Adalimumab |
| Q46611412 | Adapting to obesity with adipose tissue inflammation. |
| Q21093257 | Advances in rheumatology: new targeted therapeutics |
| Q37270827 | Alterations in peripheral blood memory B cells in patients with active rheumatoid arthritis are dependent on the action of tumour necrosis factor |
| Q90263467 | An Effective Method for Acute Vagus Nerve Stimulation in Experimental Inflammation |
| Q30438726 | An update on the classification and treatment of vasculitic neuropathy |
| Q64075128 | Anti-TNF Therapy in Spondyloarthritis and Related Diseases, Impact on the Immune System and Prediction of Treatment Responses |
| Q33960066 | Anti-TNF-alpha therapies in systemic lupus erythematosus |
| Q83986921 | Anti-TNFα therapy may lead to blood pressure reductions through improved endothelium-dependent microvascular function in patients with rheumatoid arthritis |
| Q34348277 | Anti-TNFα therapy transiently improves high density lipoprotein cholesterol levels and microvascular endothelial function in patients with rheumatoid arthritis: a pilot study. |
| Q64235362 | Anti-receptor activator of nuclear factor kappa-B ligand antibody treatment increases osteoclastogenesis-promoting interleukin-8 in patients with rheumatoid arthritis |
| Q36287340 | Anti-rheumatic treatment is not associated with reduction of pentraxin 3 in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis |
| Q36633289 | Anti-tumour necrosis factor alpha therapy improves insulin sensitivity in normal-weight but not in obese patients with rheumatoid arthritis. |
| Q24683949 | Antibody targeting of TIRC7 results in significant therapeutic effects on collagen-induced arthritis in mice |
| Q33284147 | Arthritis suppression by NADPH activation operates through an interferon-beta pathway |
| Q54318379 | Association of TNF-α and Fas gene promoter polymorphism with the risk of Kashin-Beck disease in Northwest Chinese population. |
| Q48252369 | Association of the PDE3A-SLCO1C1 locus with the response to anti-TNF agents in psoriasis. |
| Q35125828 | Autoimmune sensorineural hearing loss: an immunologic perspective |
| Q35558406 | Autoinflammation: translating mechanism to therapy |
| Q27308865 | Bio-imaging and Photodynamic Therapy with Tetra Sulphonatophenyl Porphyrin (TSPP)-TiO2 Nanowhiskers: New Approaches in Rheumatoid Arthritis Theranostics |
| Q35770347 | Bioinformatics-Based Identification of MicroRNA-Regulated and Rheumatoid Arthritis-Associated Genes |
| Q35052847 | Biological roles of CCAAT/Enhancer-binding protein delta during inflammation |
| Q37968143 | Biologics-based therapy for the treatment of rheumatoid arthritis |
| Q39131281 | Bone-targeting endogenous secretory receptor for advanced glycation end products rescues rheumatoid arthritis |
| Q51799490 | CD147 promotes IKK/IκB/NF-κB pathway to resist TNF-induced apoptosis in rheumatoid arthritis synovial fibroblasts. |
| Q37635350 | CD14brightCD16+ intermediate monocytes are induced by interleukin-10 and positively correlate with disease activity in rheumatoid arthritis. |
| Q34654024 | CD3-specific antibodies: a portal to the treatment of autoimmunity |
| Q35919881 | CD69 downregulates autoimmune reactivity through active transforming growth factor-beta production in collagen-induced arthritis. |
| Q24568066 | Canonical pathway of nuclear factor kappa B activation selectively regulates proinflammatory and prothrombotic responses in human atherosclerosis |
| Q35749068 | Cartilage destruction mediated by synovial fibroblasts does not depend on proliferation in rheumatoid arthritis |
| Q44996519 | Cavitating pneumonia after treatment with infliximab and prednisone |
| Q37126944 | Characterization of the complex formed between a potent neutralizing ovine-derived polyclonal anti-TNFα Fab fragment and human TNFα. |
| Q40914680 | Chemical Hypoxia Brings to Light Altered Autocrine Sphingosine-1-Phosphate Signalling in Rheumatoid Arthritis Synovial Fibroblasts |
| Q90243369 | Chromatin activity at GWAS loci identifies T cell states driving complex immune diseases |
| Q89736197 | Chronic Adipose Tissue Inflammation Linking Obesity to Insulin Resistance and Type 2 Diabetes |
| Q59062762 | Chronic polyarthritis caused by mammalian DNA that escapes from degradation in macrophages |
| Q28069373 | Claims Data Analysis of Tumor Necrosis Factor Inhibitor Treatment Dosing Among Patients with Rheumatoid Arthritis: A Systematic Review of Methods |
| Q38036230 | Clinical immunologic interventions for the treatment of type 1 diabetes |
| Q85965096 | Comparison of tuberculosis incidence in ankylosing spondylitis and rheumatoid arthritis during tumor necrosis factor inhibitor treatment in an intermediate burden area |
| Q42971266 | Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy |
| Q35190025 | Contrasting effects of TNF and anti-TNF on the activation of effector T cells and regulatory T cells in autoimmunity |
| Q36370439 | Critical role of the carboxyl terminus of proline-rich tyrosine kinase (Pyk2) in the activation of human neutrophils by tumor necrosis factor: separation of signals for the respiratory burst and degranulation |
| Q37115465 | Crystallization and preliminary X-ray analysis of the tumour necrosis factor alpha-tumour necrosis factor receptor type 2 complex |
| Q64263056 | Cubic and hexagonal liquid crystals as drug carriers for the transdermal delivery of triptolide |
| Q38986062 | Cytokines and Chemokines in Mycobacterium tuberculosis Infection |
| Q22306446 | Cytokines and cytokine profiles in human autoimmune diseases and animal models of autoimmunity |
| Q89519878 | Deciphering the Active Ingredients and Molecular Mechanisms of Tripterygium hypoglaucum (Levl.) Hutch against Rheumatoid Arthritis Based on Network Pharmacology |
| Q35202064 | Defining immunological impact and therapeutic benefit of mild heating in a murine model of arthritis |
| Q36148416 | Design of effective immunotherapy for human autoimmunity |
| Q46941346 | Differential effect of conditioning regimens on cytokine responses during allogeneic stem cell transplantation. |
| Q40165582 | Discovery of dual inhibitors of the immune cell PI3Ks p110delta and p110gamma: a prototype for new anti-inflammatory drugs |
| Q37092653 | Dissection of antiviral and immune regulatory functions of tumor necrosis factor receptors in a chronic lymphocytic choriomeningitis virus infection. |
| Q89917602 | Distinct tribological endotypes of pathological human synovial fluid reveal characteristic biomarkers and variation in efficacy of viscosupplementation at reducing local strains in articular cartilage |
| Q26739150 | Effect of Anti-TNF Antibodies on Clinical Response in Rheumatoid Arthritis Patients: A Meta-Analysis |
| Q91923341 | Effect of biologics in the level of cytokines in the synovial fluid of patients with ankylosing spondylitis |
| Q64102310 | Effector Functions of CD4+ T Cells at the Site of Local Autoimmune Inflammation-Lessons From Rheumatoid Arthritis |
| Q26773076 | Effects of Environmental Factors on Soluble Expression of a Humanized Anti-TNF-α scFv Antibody in Escherichia coli |
| Q48020807 | Effects of tripolyphosphate on cellular uptake and RNA interference efficiency of chitosan-based nanoparticles in Raw 264.7 macrophages. |
| Q38188862 | Emerging immunotherapies for rheumatoid arthritis. |
| Q38182971 | Emerging role of endosomal toll-like receptors in rheumatoid arthritis |
| Q35745027 | Epicutaneous immunization with type II collagen inhibits both onset and progression of chronic collagen-induced arthritis |
| Q35589934 | Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). |
| Q39542019 | Expression and purification of a natural N-terminal pre-ligand assembly domain of tumor necrosis factor receptor 1 (TNFR1 PLAD) and preliminary activity determination |
| Q39696464 | Expression of costimulatory TNFR2 induces resistance of CD4+FoxP3- conventional T cells to suppression by CD4+FoxP3+ regulatory T cells. |
| Q54590319 | Expression of non-signaling membrane-anchored death receptors protects murine livers in different models of hepatitis. |
| Q35838456 | Extracellular cyclophilin A possesses chemotaxic activity in cattle |
| Q34987311 | Fc receptors are major mediators of antibody based inflammation in autoimmunity |
| Q54459559 | GDF-5 is suppressed by IL-1beta and enhances TGF-beta3-mediated chondrogenic differentiation in human rheumatoid fibroblast-like synoviocytes. |
| Q35647868 | Genetic, cellular and immune approaches to disease therapy: past and future |
| Q28274196 | Graves' ophthalmopathy |
| Q33815758 | Humanization and characterization of an anti-human TNF-α murine monoclonal antibody |
| Q36872163 | Hyperoside exerts anti-inflammatory and anti-arthritic effects in LPS-stimulated human fibroblast-like synoviocytes in vitro and in mice with collagen-induced arthritis |
| Q37980338 | Hypoxia--a key regulator of angiogenesis and inflammation in rheumatoid arthritis |
| Q50021688 | IL-1β (Interleukin-1β) and TNF-α (Tumor Necrosis Factor-α) Impact Abdominal Aortic Aneurysm Formation by Differential Effects on Macrophage Polarization |
| Q29547525 | IL-23 drives a pathogenic T cell population that induces autoimmune inflammation |
| Q33193935 | Identification of anti-TNFα peptides with consensus sequence |
| Q34158461 | IkappaBbeta acts to inhibit and activate gene expression during the inflammatory response |
| Q26823714 | Immune-regulatory mechanisms in systemic autoimmune and rheumatic diseases |
| Q80947640 | Immunology |
| Q47100950 | Immunology of Gut-Bone Signaling. |
| Q34484801 | Immunosuppressive Medications |
| Q37325451 | Immunotherapy of autoimmunity and cancer: the penalty for success |
| Q92724492 | Improved monovalent TNF receptor 1-selective inhibitor with novel heterodimerizing Fc |
| Q34356481 | In search of magic bullets: the golden age of immunotherapeutics. |
| Q36943794 | Inflammation activation and resolution in human tendon disease |
| Q36975464 | Inflammation-independent defective early B cell tolerance checkpoints in rheumatoid arthritis. |
| Q44286589 | Inflammation: A nervous connection |
| Q35925068 | Inflammatory networks underlying colorectal cancer |
| Q35565652 | Inhibition of 4-1BBL-regulated TLR response in macrophages ameliorates endotoxin-induced sepsis in mice |
| Q39912703 | Inhibition of destructive autoimmune arthritis in FcgammaRIIa transgenic mice by small chemical entities |
| Q24793412 | Inhibition of established collagen-induced arthritis with a tumour necrosis factor-alpha inhibitor expressed from a self-contained doxycycline regulated plasmid |
| Q35061951 | Inhibition of synovitis and joint destruction by a new single domain antibody specific for cyclophilin A in two different mouse models of rheumatoid arthritis |
| Q39176347 | Inhibitory effect of sodium houttuyfonate on synovial proliferation in vitro in cells from a patient with rheumatoid arthritis |
| Q38553533 | Interferon regulatory factor 5 in human autoimmunity and murine models of autoimmune disease. |
| Q42058247 | Interleukin-15 and interferon-gamma participate in the cross-talk between natural killer and monocytic cells required for tumour necrosis factor production |
| Q88562718 | Interleukin-6: designing specific therapeutics for a complex cytokine |
| Q46128520 | Intravitreal Infliximab Injection to Treat Experimental Endophthalmitis |
| Q42273902 | Investigation of the role of endosomal Toll-like receptors in murine collagen-induced arthritis reveals a potential role for TLR7 in disease maintenance |
| Q82054014 | IκBβ is a positive and negative regulator of NF-κB activity during inflammation |
| Q54301830 | K/B×N serum transfer arthritis is delayed and less severe in leukaemia inhibitory factor (LIF)-deficient mice. |
| Q35274375 | Lack of gp130 expression in hepatocytes attenuates tumor progression in the DEN model |
| Q34207981 | Making sense out of massive data by going beyond differential expression |
| Q37784871 | Mechanisms of TNFα regulation in uveitis: Focus on RNA-binding proteins |
| Q26748868 | Metabolic Inflammation-Differential Modulation by Dietary Constituents |
| Q37279851 | MicroRNA-124 mediates the cholinergic anti-inflammatory action through inhibiting the production of pro-inflammatory cytokines |
| Q52642682 | Mild hypothermia upregulates myc and xbp1s expression and improves anti-TNFα production in CHO cells. |
| Q54957720 | Molecular targets of Chinese herbs: a clinical study of metastatic colorectal cancer based on network pharmacology. |
| Q35026014 | Monoclonal antibodies in immune and inflammatory diseases |
| Q35869016 | Morphological characterization of intra-articular HMGB1 expression during the course of collagen-induced arthritis. |
| Q34023923 | Myelitis and optic neuritis induced by a long course of etanercept in a patient with rheumatoid arthritis |
| Q37449635 | NF-κB signaling and bone resorption |
| Q36831531 | NLRP3 inflammasome plays a redundant role with caspase 8 to promote IL-1β-mediated osteomyelitis |
| Q92444080 | New Engineered-Botulinum Toxins Inhibit the Release of Pain-Related Mediators |
| Q52855355 | Nonresponse to tumor necrosis factor antagonists--is there any point in re-treatment? |
| Q81096216 | Novel therapies for anti-neutrophil cytoplasmic antibody-associated vasculitis |
| Q37209671 | Nuclear receptors in inflammation control: repression by GR and beyond. |
| Q64118754 | P38 and JNK Mitogen-Activated Protein Kinases Interact With Chikungunya Virus Non-structural Protein-2 and Regulate TNF Induction During Viral Infection in Macrophages |
| Q43469385 | PanR1, a dominant negative missense allele of the gene encoding TNF-alpha (Tnf), does not impair lymphoid development |
| Q42713856 | Paradoxical roles of tumour necrosis factor-alpha in prostate cancer biology |
| Q36090203 | Pathological role of osteoclast costimulation in arthritis-induced bone loss. |
| Q37169930 | Pentoxifylline attenuates nociceptive sensitization and cytokine expression in a tibia fracture rat model of complex regional pain syndrome |
| Q38820131 | Peripheral Tumor Necrosis Factor-Alpha (TNF-α) Modulates Amyloid Pathology by Regulating Blood-Derived Immune Cells and Glial Response in the Brain of AD/TNF Transgenic Mice |
| Q62633601 | Pharmacokinetics, Safety, and Tolerability of the Dual Inhibitor of Tumor Necrosis Factor-α and Interleukin 17A, ABBV-257, in Healthy Volunteers and Patients With Rheumatoid Arthritis |
| Q38685181 | Pharmacological Properties and Molecular Mechanisms of Thymol: Prospects for Its Therapeutic Potential and Pharmaceutical Development |
| Q47101484 | Pharmacological Regulation of Neuropathic Pain Driven by Inflammatory Macrophages |
| Q86283640 | Phellinus baumii ethyl acetate extract alleviated collagen type II induced arthritis in DBA/1 mice |
| Q46634751 | Phospholipase D1 plays a key role in TNF-alpha signaling |
| Q28118730 | Phosphorylation of FOXP3 controls regulatory T cell function and is inhibited by TNF-α in rheumatoid arthritis |
| Q51828636 | Precision Medicine in Inflammatory Bowel Diseases. |
| Q101237324 | Preclinical validation of therapeutic targets predicted by tensor factorization on heterogeneous graphs |
| Q36322970 | Prevalence and pharmacological modulation of humoral immunity to AAV vectors in gene transfer to synovial tissue |
| Q38842945 | Pro-inflammatory cytokines in cryptoglandular anal fistulas. |
| Q28077781 | Profile of adalimumab and its potential in the treatment of uveitis |
| Q46041262 | Prostaglandin E2 enhances Th17 responses via modulation of IL-17 and IFN-gamma production by memory CD4+ T cells |
| Q34484614 | Protective effect of topical Cordia verbenacea in a rat periodontitis model: immune-inflammatory, antibacterial and morphometric assays |
| Q42728050 | Protein kinase C-theta mediates negative feedback on regulatory T cell function |
| Q36823637 | Pulmonary nodules in an infliximab-treated rheumatoid arthritis patient: a clinical pathology conference held by the Division of Rheumatology at Hospital for Special Surgery |
| Q41912868 | RANKL cytokine enhances TNF-induced osteoclastogenesis independently of TNF receptor associated factor (TRAF) 6 by degrading TRAF3 in osteoclast precursors |
| Q37251620 | Reactive oxygen species mediate TNFR1 increase after TRPV1 activation in mouse DRG neurons |
| Q41893567 | Regulation of inflammatory responses in tumor necrosis factor-activated and rheumatoid arthritis synovial macrophages by JAK inhibitors |
| Q80547506 | Resistance to development of collagen-induced arthritis in C57BL/6 mice is due to a defect in secondary, but not in primary, immune response |
| Q36755055 | Resting CD4+ effector memory T cells are precursors of bystander-activated effectors: a surrogate model of rheumatoid arthritis synovial T-cell function. |
| Q41236945 | Role of glucocorticoid-induced leucine zipper (GILZ) in inflammatory bone loss. |
| Q34428921 | Role of macrophage CCAAT/enhancer binding protein delta in the pathogenesis of rheumatoid arthritis in collagen-induced arthritic mice. |
| Q34619592 | SOCS-3 negatively regulates innate and adaptive immune mechanisms in acute IL-1-dependent inflammatory arthritis |
| Q39276466 | SP and IL-33 together markedly enhance TNF synthesis and secretion from human mast cells mediated by the interaction of their receptors. |
| Q92615849 | Salivary interleukin 6, interleukin 8, interleukin 17A, and tumour necrosis factor α levels in patients with periodontitis and rheumatoid arthritis |
| Q34601386 | Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism |
| Q52903912 | Serum TNF-α, B2M and sIL-2R levels are biological correlates of outcome in adjuvant IFN-α2b treatment of patients with melanoma. |
| Q42279214 | Serum cytokine concentrations in a patient with rheumatoid arthritis on etanercept therapy who subsequently developed pneumocystis pneumonia: a case report |
| Q36410999 | Shiga Toxins Activate the NLRP3 Inflammasome Pathway To Promote Both Production of the Proinflammatory Cytokine Interleukin-1β and Apoptotic Cell Death |
| Q91181828 | Silencing Leukocyte Immunoglobulin-Like Receptor A1 in Monocytes Inhibits Inflammation in Mice with Multiple Sclerosis |
| Q28248678 | Single domain antibodies: promising experimental and therapeutic tools in infection and immunity |
| Q64101100 | Single-cell correlations of mRNA and protein content in a human monocytic cell line after LPS stimulation |
| Q98461110 | Small and Long Non-coding RNAs as Functional Regulators of Bone Homeostasis, Acting Alone or Cooperatively |
| Q33635992 | Solvent Selection for Insoluble Ligands, a Challenge for Biological Assay Development: A TNF-α/SPD304 Study |
| Q47563599 | Stemodia maritima L. Extract Decreases Inflammation, Oxidative Stress, and Alveolar Bone Loss in an Experimental Periodontitis Rat Model |
| Q39904158 | Sterile signals generate weaker and delayed macrophage NLRP3 inflammasome responses relative to microbial signals |
| Q35251283 | Sustained release myofascial release as treatment for a patient with complications of rheumatoid arthritis and collagenous colitis: a case report |
| Q34162687 | Synthesis of novel tylophorine derivatives and evaluation of their anti-inflammatory activity |
| Q36688370 | T cell-directed therapies: lessons learned and future prospects |
| Q37642265 | TNF Blockade Maintains an IL-10+ Phenotype in Human Effector CD4+ and CD8+ T Cells |
| Q35849817 | TNF downmodulates the function of human CD4+CD25hi T-regulatory cells |
| Q36862101 | TNF signaling contributes to the development of nociceptive sensitization in a tibia fracture model of complex regional pain syndrome type I |
| Q37696079 | TNF-alpha: an activator of CD4+FoxP3+TNFR2+ regulatory T cells. |
| Q24634905 | TNF-stimulated MAP kinase activation mediated by a Rho family GTPase signaling pathway |
| Q35858771 | TNFα induces inflammatory stress response in microvascular endothelial cells via Akt- and P38 MAP kinase-mediated thrombospondin-1 expression |
| Q90726860 | TNFα inhibitors exacerbate Mycobacterium paratuberculosis infection in tissue culture: a rationale for poor response of patients with Crohn's disease to current approved therapy |
| Q34570319 | TNFα promotes Th17 cell differentiation through IL-6 and IL-1β produced by monocytes in rheumatoid arthritis |
| Q55091012 | The Many Facets of Sphingolipids in the Specific Phases of Acute Inflammatory Response. |
| Q35113537 | The Mast Cell in Inflammatory Arthritis |
| Q64882605 | The Role of Efferocytosis in Autoimmune Diseases. |
| Q92327996 | The Role of Systemic Inflammation in Cancer-Associated Muscle Wasting and Rationale for Exercise as a Therapeutic Intervention |
| Q36094314 | The alpha7 nicotinic acetylcholine receptor as a pharmacological target for inflammation. |
| Q24812699 | The contact-mediated response of peripheral-blood monocytes to preactivated T cells is suppressed by serum factors in rheumatoid arthritis |
| Q37681930 | The degree of CD4+ T cell autoreactivity determines cellular pathways underlying inflammatory arthritis |
| Q24817093 | The differential contribution of tumour necrosis factor to thermal and mechanical hyperalgesia during chronic inflammation |
| Q55217201 | The economic case for precision medicine. |
| Q36153190 | The gut microbiota regulates bone mass in mice |
| Q53334056 | The inhibition of TNF-alpha anti-tumoral properties by blocking antibodies promotes tumor growth in a rat model. |
| Q35011702 | The many faces of tumor necrosis factor in stroke |
| Q52888237 | The multifaceted balance of TNF-α and type I/II interferon responses in SLE and RA: how monocytes manage the impact of cytokines. |
| Q37883460 | The phenotypic and functional consequences of tumour necrosis factor receptor type 2 expression on CD4(+) FoxP3(+) regulatory T cells. |
| Q24799403 | The role and clinical implications of G6PI in experimental models of rheumatoid arthritis |
| Q37268896 | The role of T cells in osteoporosis, an update. |
| Q35630135 | The role of synovial macrophages and macrophage-produced cytokines in driving aggrecanases, matrix metalloproteinases, and other destructive and inflammatory responses in osteoarthritis |
| Q38149127 | The roles of inflammatory cytokines in the pathogenesis of ossification of ligamentum flavum |
| Q85932922 | The use of an interferon-gamma release assay as a biomarker of response to anti-TNF-alpha treatment |
| Q36214006 | The vagus nerve and the nicotinic anti-inflammatory pathway |
| Q33304428 | Therapeutic effect of a poly(ADP-ribose) polymerase-1 inhibitor on experimental arthritis by downregulating inflammation and Th1 response |
| Q80207327 | Therapeutic efficacy and safety of chaperonin 10 in patients with rheumatoid arthritis: a double-blind randomised trial |
| Q27002391 | Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling |
| Q36490256 | Therapeutic targeting of the inflammome |
| Q38204742 | Toad glandular secretions and skin extractions as anti-inflammatory and anticancer agents |
| Q55248422 | Trivalent soluble TNF Receptor, a potent TNF-α antagonist for the treatment collagen-induced arthritis. |
| Q37021677 | Tumor necrosis factor neutralization combined with chemotherapy enhances Mycobacterium tuberculosis clearance and reduces lung pathology |
| Q49021460 | Tumor necrosis factor-alpha neutralization reduced cerebral edema through inhibition of matrix metalloproteinase production after transient focal cerebral ischemia |
| Q35215812 | Tumour necrosis factor alpha: a potential target for the therapy of solid tumours. |
| Q61819217 | Tumour necrosis factor and cancer |
| Q35086227 | Two dosing regimens of certolizumab pegol in patients with active rheumatoid arthritis |
| Q34905862 | Unphosphorylated STAT3 modulates alpha 7 nicotinic receptor signaling and cytokine production in sepsis |
| Q38947622 | Up-to-Date Applications of Microarrays and Their Way to Commercialization |
| Q36588861 | Use of biologics in rheumatoid arthritis: where are we going? |
| Q38877668 | Validity of SW982 synovial cell line for studying the drugs against rheumatoid arthritis in fluvastatin-induced apoptosis signaling model |
| Q37541158 | Viscosupplementation with intra-articular hyaluronic acid for hip disorders. A systematic review and meta-analysis |
| Q35118364 | What is the future of targeted therapy in rheumatology: biologics or small molecules? |
| Q34369064 | Women and autoimmune diseases |
| Q88574775 | [New antirheumatics : Advances for patients and society] |
| Q73580201 | [Target therapy with monoclonal antibodies] |
| Q24298778 | bri3, a novel gene, participates in tumor necrosis factor-alpha-induced cell death |
| Q34247201 | iRhom2 regulation of TACE controls TNF-mediated protection against Listeria and responses to LPS |
| Q50130534 | iRhom2-mediated proinflammatory signalling regulates heart repair following myocardial infarction |
Search more.